BIO moves 2020 international convention online

The Biotechnology Innovation Organization (BIO) has converted its 2020 international convention into an entirely online experience, BIO Digital.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Big Pharma

Will Big Pharma get the bug for microbiome therapies?

6 May 2020 The exciting field of microbiome therapeutics offers many opportunities for ‘Big Pharma’ players that are staring over the exclusivity cliff, say Craig Thomson, Leena Contarino and Andrew Wells of HGF.

Americas

Vir Biotech partners with WuXi on COVID-19 antibody treatment

27 February 2020 Immunology-focused Vir Biotechnology and Hong Kong-based WuXi Biologics have become the latest companies to turn their focus to developing treatments for the novel coronavirus.

Big Pharma

Sanofi announces new vaccine project as Australia begins animal tests

2 April 2020 France’s Sanofi Pasteur and US biotechnology company Translate Bio have joined the race to develop a vaccine for SARS-CoV-2, the coronavirus behind COVID-19.

More on this story

Big Pharma

Sanofi announces new vaccine project as Australia begins animal tests

2 April 2020 France’s Sanofi Pasteur and US biotechnology company Translate Bio have joined the race to develop a vaccine for SARS-CoV-2, the coronavirus behind COVID-19.

Americas

Vir Biotech partners with WuXi on COVID-19 antibody treatment

27 February 2020 Immunology-focused Vir Biotechnology and Hong Kong-based WuXi Biologics have become the latest companies to turn their focus to developing treatments for the novel coronavirus.

Big Pharma

Will Big Pharma get the bug for microbiome therapies?

More on this story

Big Pharma

Sanofi announces new vaccine project as Australia begins animal tests

2 April 2020 France’s Sanofi Pasteur and US biotechnology company Translate Bio have joined the race to develop a vaccine for SARS-CoV-2, the coronavirus behind COVID-19.

Americas

Vir Biotech partners with WuXi on COVID-19 antibody treatment

27 February 2020 Immunology-focused Vir Biotechnology and Hong Kong-based WuXi Biologics have become the latest companies to turn their focus to developing treatments for the novel coronavirus.

Big Pharma

Will Big Pharma get the bug for microbiome therapies?